154 related articles for article (PubMed ID: 20843134)
1. Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia.
Sailaja K; Surekha D; Rao DN; Rao DR; Vishnupriya S
Asian Pac J Cancer Prev; 2010; 11(2):461-4. PubMed ID: 20843134
[TBL] [Abstract][Full Text] [Related]
2. Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients.
Makhtar SM; Husin A; Baba AA; Ankathil R
J Genet; 2017 Sep; 96(4):633-639. PubMed ID: 28947711
[TBL] [Abstract][Full Text] [Related]
3. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
[TBL] [Abstract][Full Text] [Related]
4. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
5. Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia.
Delmond KA; Delleon H; Goveia RM; Teixeira TM; Abreu DC; Mello-Andrade F; Reis AADS; Silva DME; Barbosa ADP; Tavares RS; Anunciação CE; Silveira-Lacerda E
Mol Biol Rep; 2021 Mar; 48(3):2035-2046. PubMed ID: 33709282
[TBL] [Abstract][Full Text] [Related]
6. Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia.
Davies A; Giannoudis A; Zhang JE; Austin G; Wang L; Holyoake TL; Müller MC; Foroni L; Kottaridis PD; Pirmohamed M; Clark RE
Clin Pharmacol Ther; 2014 Dec; 96(6):694-703. PubMed ID: 25188725
[TBL] [Abstract][Full Text] [Related]
7. MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Liu YC; Hsiao HH; Yang WC; Liu TC; Chang CS; Yang MY; Lin PM; Hsu JF; Lee CP; Lin SF
Mol Carcinog; 2014 Dec; 53(12):951-9. PubMed ID: 23818300
[TBL] [Abstract][Full Text] [Related]
8. Glutathione S-transferase P1 genotype and prognosis in Hodgkin's lymphoma.
Hohaus S; Di Ruscio A; Di Febo A; Massini G; D'Alo' F; Guidi F; Mansueto G; Voso MT; Leone G
Clin Cancer Res; 2005 Mar; 11(6):2175-9. PubMed ID: 15788664
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphism of the glutathione-S-transferase P1 gene (GSTP1) and susceptibility to prostate cancer in the Kashmiri population.
Qadri Q; Sameer AS; Shah ZA; Hamid A; Alam S; Manzoor S; Siddiqi MA
Genet Mol Res; 2011 Dec; 10(4):3038-45. PubMed ID: 22180037
[TBL] [Abstract][Full Text] [Related]
10. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
12. [Research advance on molecular genetics of CML blast crisis].
Zhu HQ; Zhang S; Liu XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935
[TBL] [Abstract][Full Text] [Related]
13. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese.
Zhong SL; Zhou SF; Chen X; Chan SY; Chan E; Ng KY; Duan W; Huang M
Eur J Pharm Sci; 2006 May; 28(1-2):77-85. PubMed ID: 16488119
[TBL] [Abstract][Full Text] [Related]
14. Ile105Val GSTP1 polymorphism and susceptibility to colorectal carcinoma in Bulgarian population.
Vlaykova T; Miteva L; Gulubova M; Stanilova S
Int J Colorectal Dis; 2007 Oct; 22(10):1209-15. PubMed ID: 17404745
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
16. [Tyrosine kinase inhibitors for the treatment of CML].
Heim D
Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455
[TBL] [Abstract][Full Text] [Related]
17. Glutathione S-transferase gene polymorphic sequence variations: Association with risk and response to Imatinib among Chronic Myeloid Leukemia patients of Kashmir.
Baba SM; Shah ZA; Pandith AA; Geelani SA; Mir MM; Bhat JR; Gul A; Bhat GM
Int J Lab Hematol; 2021 Oct; 43(5):1000-1008. PubMed ID: 33470551
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T
Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
